Press release

TargEDys extends Series A and appoints new Board Members

Rouen, 04 April 2017 – TargEDys, which develops innovative microbiome-based solutions to regulate the appetite, has extended its Series A by 3.5 million Euro from Zaluvida, which joins existing investors Seventure Partners, NCI and Pontifax. In parallel, the TargEDys Board of Directors welcomes three new members.

Zaluvida invests in TargEDys

Zaluvida’s investment of 3.5 million euro in TargEDys supplements the initial 5.8 million euro raised in April 2016, and its non-dilutive funding of 1.1 million euro by Bpifrance in March 2017. This additional investment will allow to accelerate and strengthen the development of TargEDys technologies and products.

TargEDys builds on the work of professors Serguei Fetissov and Pierre Déchelotte, from the University of Rouen, who were the first to identify a molecular mechanism of the ”gut-brain” axis. Based on this discovery, TargEDys is developing two appetite-regulation products:

- **ProbioSatys** targets overweight through bacteria producing a protein with effects similar to α - MSH, the human satiety hormone. This product has demonstrated its effectiveness in various preclinical models. 1.4 billion people are overweight globally, as are 60% of the population of developed countries.

- **ProbioNutrys** is based on the same principle, but acts in reverse via another species of bacteria by stimulating appetite. It is intended for seniors suffering from malnourishment, cachectic or anorexic patients. Elderly people are particularly concerned by malnutrition. This phenomenon affects 4 to 10% of those who stay at home and reaches 30 to 70% of those who are hospitalized.

“In addition to its contribution to our capital, Zaluvida’s know-how is very valuable to TargEDys’ development, in particular in terms of access to the market and marketing,” reports Grégory Lambert, CEO of TargEDys.

Christoph Staeuble, Zaluvida Group CEO commented:

“TargEDys is well positioned at the forefront of human microbiome research and development, which I personally consider to be the ultimate frontier to address the obesity epidemic, therefore I am delighted that we are creating a partnership of like-minded teams to expedite the commercialization of these breakthrough solutions.”

Building on these new strengths, TargEDys hopes to quickly position itself among the global leaders in appetite regulation.

**Three new members have joined the Board of Directors of TargEDys: Christoph Staeuble, Matthias Miller and Danilo Casadei-Massari.**

About the new members
**Christoph Staeuble, CEO, Zaluvida Group.**
Chris is a proven business leader with a track record of delivering exceptional business results in FMCG and SMCG industries. He spent the initial 17 years of his career with P&G, last as Managing Director Health Care, before joining Omega Pharma as Chief Operating Officer in 2010. He led Omega Pharma into the Top 5 of the European OTC industry then joined Zaluvida on July 1, 2016.

**Matthias Miller, Chief Scientific Officer, Zaluvida Group.**
Matthias’ expertise lies in bringing product concepts through to development and clinical trials. He is a registered pharmacist and has a Masters degree in Clinical Trial Management. Prior to his appointment as Chief Scientific Officer at Zaluvida, Matthias served as COO of analyze & realize GmbH, a Berlin based life science consultancy and clinical research company. From 1987 till 2006, he worked in managing positions with German and international companies operating in the field of natural health & food products.

**Danilo Casadei-Massari**
Danilo has extensive experience as a senior pharmaceutical executive and as a highly successful serial entrepreneur. Most recently he was a founder and President of CM&D Pharma Ltd, a medical foods company he founded in 2007 and sold to Nestle Health Science in 2011. He is currently a Director on the boards of companies based in the USA, Italy, Ireland, Finland and France as well as a Cofounder in some of them. Danilo is an expert in start-ups and co-ventures in the pharmaceutical sector.

The Board of Directors of TargEDys, is now composed of

- Danilo Casadei-Massari, Independent Director,
- Isabelle de Crémoux, representing Seventure Partners
- Pierre Déchelotte, Chairman
- Eric de La Fortelle, representing Seventure Partners
- Ohad Hammer, representing Pontifax,
- Grégory Lambert, CEO
- Christoph Staeuble, representing the Zaluvida group

As well as two Board observers, Laurie Périé from NCI and Matthias Miller from the Zaluvida group.
About TargEDys

TargEDys is an innovative start-up whose activity is based on world-leading research from company founders Sergueï Fetissov and Pierre Déchelotte, who have identified and described the 1st molecular link of the gut-brain axis. TargEDys is dedicated to the modulation of weight and develops functional food, medical food and pharmaceutical products to harness the microbiome’s ability to regulate appetite and thus maintain or restore metabolic health. The company, which is registered in Rouen, France, started its operations in 2015, but was founded in 2011 by an international group of medical science professionals from France, USA, Sweden, Japan, Brazil and Germany. Today, the operational team consists of a synergic team combining scientific, medical, pharmaceutical development and business expertise: Grégory Lambert (CEO), Sergueï Fetissov (scientific referent) and Pierre Déchelotte (chairman of the Board and medical referent).

For more details: www.targedys.com / Twitter @TargEDys

About Zaluvida

Zaluvida an integrated global life science group lead out of it’s corporate offices in Switzerland. Our passion is creating groundbreaking health products. By using unique bioactive compounds extracted from nature, we pioneer in tackling some of the world’s big challenges like obesity, antibiotic resistance and livestock emissions. Our teams are united by the desire to use our visionary biotech innovations to help shape a better future for as many people in the world as possible.

For more details: www.zaluvida.com

About Seventure Partners

With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies in France and Germany, and Life sciences across Europe and North America.

In Life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Recently, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel
and Novartis as well as entrepreneurs and financial institutions.

Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more details: www.seventure.com / Twitter @SeventureP

About Pontifax

Pontifax is a venture capital firm focusing on groundbreaking innovations in the life sciences arena. Founded in 2004 and with $350M under management, Pontifax seeks transformative, innovative healthcare opportunities at all development stages.

For more details: http://www.pontifax.com

About NCI

NCI is an investment company operating in Normandy and in Ile de France. For more than 15 years, NCI has been investing skilled resources and equity capital in the creation, the development and the transfer of companies. With a double-digit growth track record, and about €200M under management (entrusted by public and private institutional investors), NCI strives to create sustainable value within its portfolio companies by reconciling finance, economic development and social welfare.

For more details: http://www.n-ci.com

Press contact: Maxence FORTIN
maxence.fortin@nefermedia.fr
+33 6 32 32 99 41